Form 4: Neurocrine Biosciences Executive Julie Cooke Executes Option and Sells Shares Under 10b5-1 Plan

Julie Cooke, Chief Human Resources Officer at Neurocrine Biosciences, exercised stock options and sold 10,000 shares of common stock at an average price of $140.1864 per share, according to a recent SEC filing.

Summary

• Julie Cooke, Chief Human Resources Officer of Neurocrine Biosciences, executed a transaction involving the company's stock on July 1, 2024.
• Cooke exercised options to acquire 10,000 shares of common stock at a price of $61.82 per share.
• Simultaneously, Cooke sold 10,000 shares of common stock at a weighted average price of $140.1864 per share, with individual sales ranging from $140.00 to $140.48.
• The sale was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on March 14, 2024.
• Following these transactions, Cooke directly owns 18,202 shares of Neurocrine Biosciences stock.
• Cooke also indirectly owns 16,538 shares through the Cooke Family Trust of 2004.
• She also holds options for 13,532 shares.

Sentiment

Score: 5

Explanation: Neutral sentiment. The filing simply reports a transaction executed under a pre-existing plan, with no explicit positive or negative implications.

Positives

• The exercise of stock options and subsequent sale indicates Cooke's belief in the company's long-term value, as she initially acquired the options at a lower price.

Negatives

• The sale of shares, even under a 10b5-1 plan, could be perceived negatively by some investors, although the plan mitigates concerns about insider trading.

Risks

• While the 10b5-1 plan provides a structured approach to selling shares, market fluctuations could impact the overall value realized from the sales.
• Investor sentiment could be affected by executive stock sales, regardless of the pre-planned nature of the transactions.

Industry Context

Executive stock transactions are common in publicly traded companies, and the use of 10b5-1 plans is a standard practice to avoid insider trading concerns. Investors often monitor these transactions for insights into management's perspective on the company's value.

Comparison to Industry Standards

• Executive compensation packages often include stock options to align management's interests with those of shareholders.
• Rule 10b5-1 trading plans are widely used by executives at companies like Amgen, Biogen, and Gilead to manage their stock sales in a transparent and compliant manner.
• The size and frequency of executive stock transactions can vary significantly across the biotechnology industry, depending on factors such as company size, stock performance, and individual compensation agreements.

Stakeholder Impact

• Shareholders may react to the stock sale, although the 10b5-1 plan should mitigate concerns about insider trading.
• Employees may view the transaction as a personal financial decision by the executive.

Key Dates